Neoadjuvant immune checkpoint inhibitor (ICI) therapy may enable patients with high-risk hepatocellular carcinoma (HCC) to achieve outcomes similar to those undergoing upfront surgery. Administering ...
Mikeie Reiland is a staff writer for Education at Forbes Advisor. Before coming to Forbes Advisor, he wrote magazine journalism for publications like the Oxford American, Bitter Southerner, and Gravy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback